Defeating malaria together

Interactive R&D portfolio

MMV’s portfolio focuses on delivering efficacious medicines that are affordable, accessible and appropriate for use in malaria endemic areas. Specifically, the goal is to develop products that will provide: efficacy against drug-resistant strains of Plasmodium falciparum, potential for intermittent treatments (infants and pregnancy), safety in small children (less than 6 months old), safety in pregnancy, efficacy against Plasmodium vivax (including radical cure), efficacy against severe malaria, and transmission-blocking treatment.

For more information about the global malaria portfolio, read the article: Malaria medicines: a glass half full? 

Detailed information is available below (click on the boxes) for translational, development and access projects. This interactive portfolio is updated twice a year, at 1Q and 3Q. 


* First review or approval by WHO Prequalification, or by regulatory bodies who are ICH members or observers.

 Included in portfolio after product approval.

Brand names:

1 Coartem® Dispersible)
2 Artesun® 
3 Eurartesim®
4 Pyramax® tablets and granules
5 ASAQ Winthrop® 

Target Product Profiles - represented by coloured bar(s) under the project box

____  3-day cure, artemisinin-based combination therapies

____  Combinations aiming at a new Single exposure radical cure 

____  Severe malaria and pre-referral treatment

____  Intermittent/Seasonal Malaria Chemoprevention

____  Products targeting prevention of relapse for P. vivax

Target Candidate Profiles- represented by icons

 Asexual blood stages

 Relapse prevention

 Transmission reduction




Array ( [0] => front_not [1] => site_english [2] => view_rhs-column [3] => node_landing-pages_not [4] => node_page [5] => view_related [6] => view_rhs-column-below [7] => breadcrumb [8] => internal_adverts_desktop [9] => page_interactive-rd-portfolio [10] => sitewide_desktop [11] => superfish_menu_desktop )